Phase II trial of bortezomib plus doxorubicin in hepatocellular carcinoma (E6202): a trial of the Eastern Cooperative Oncology Group
β Scribed by Ciombor, Kristen K.; Feng, Yang; Benson, Al Bowen; Su, Yingjun; Horton, Linda; Short, Sarah P.; Kauh, John Sae Wook; Staley, Charles; Mulcahy, Mary; Powell, Mark; Amiri, Katayoun I.; Richmond, Ann; Berlin, Jordan
- Book ID
- 125358952
- Publisher
- Springer US
- Year
- 2014
- Tongue
- English
- Weight
- 343 KB
- Volume
- 32
- Category
- Article
- ISSN
- 0167-6997
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## Background: Malignant tumors of the salivary glands make up approximately 5% of head and neck cancers. the eastern cooperative oncology group (ecog) initiated a phase ii evaluation of paclitaxel in patients with locally recurrent or metastatic salivary gland malignancies. ## Methods: Chemo-nai
## Abstract ## BACKGROUND The current study was conducted to evaluate the antitumor activity and toxicity of gemcitabine in patients with advanced sarcoma. ## METHODS Twentyβfive patients with advanced sarcomas, who previously were untreated for metastatic disease, were treated on an Eastern Coo
## Background. Trimetrexate is an antifol that differs from methotrexate in ways that may be clinically important. Because methotrexate has activity in advanced bladder cancer, this trial was initiated.